Director at Klotho Neurosciences (KLTO) awarded 350,000 stock shares

Rhea-AI Filing Summary

ZENTMAN SAMUEL M reported acquisition or exercise transactions in this Form 4 filing.

Klotho Neurosciences, Inc. director Samuel M. Zentman reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded at a stated price of $0.00 per share as a grant under the company’s Equity Incentive Plan.

Following this equity award, Zentman’s directly held Common Stock increased to 1,086,440 shares. This filing reflects a non-cash stock grant that further aligns the director’s ownership with the company’s performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ZENTMAN SAMUEL M

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		350,000	A	(1)	1,086,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.

Remarks:

	Samuel Zentman	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Klotho Neurosciences (KLTO) report on this Form 4?

Klotho Neurosciences reported that director Samuel M. Zentman received a grant of 350,000 shares of Common Stock. The award was reported as an acquisition on March 4, 2026 and classified as a grant, award, or other acquisition.

How many Klotho Neurosciences (KLTO) shares were granted to the director?

Director Samuel M. Zentman was granted 350,000 shares of Common Stock. This stock grant was recorded at a stated price of $0.00 per share and is categorized as a grant or award acquisition under the company’s equity compensation arrangements.

What is Samuel M. Zentman’s total Klotho Neurosciences share ownership after the grant?

After the reported grant, Samuel M. Zentman directly owns 1,086,440 shares of Common Stock of Klotho Neurosciences. This total reflects the newly awarded 350,000-share grant added to his previously held direct Common Stock position.

At what price per share was the Klotho Neurosciences (KLTO) stock grant recorded?

The 350,000-share grant to director Samuel M. Zentman was recorded at a stated transaction price of $0.00 per share. This indicates the award was a non-cash equity grant rather than an open-market purchase for cash consideration.

Under what plan did Klotho Neurosciences (KLTO) grant the 350,000 shares?

The footnote states that the reporting person received the 350,000 shares as a grant under the company’s Equity Incentive Plan. This indicates the award was part of Klotho Neurosciences’ structured equity compensation program for eligible participants such as directors.

What transaction code was used for the Klotho Neurosciences (KLTO) director’s share grant?

The transaction used code “A”, which stands for grant, award, or other acquisition. It is classified as a non-derivative acquisition of Common Stock, reflecting an equity award rather than a market purchase or sale of Klotho Neurosciences shares.